# OnCo record paper-angerilli-her2-gallbladder-extrahepatic-concordance-hum-pathol-2026 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-angerilli-her2-gallbladder-extrahepatic-concordance-hum-pathol-2026/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-angerilli-her2-gallbladder-extrahepatic-concordance-hum-pathol-2026" ;
  schema:name "HER2 status in extrahepatic cholangiocarcinoma and gallbladder carcinoma: Concordance between immunohistochemistry and chromogenic in situ hybridization in 140 Cases"@en ;
  schema:description "In 140 resected bile duct and gallbladder cancers tested the way the zanidatamab trial did, about one in eleven was HER2-positive, and the HER2 signal was often patchy, present in under half the tumour cells."@en ;
  schema:url <https://onco.cc/key-papers/paper-angerilli-her2-gallbladder-extrahepatic-concordance-hum-pathol-2026/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/j.humpath.2026.106234>, <https://pubmed.ncbi.nlm.nih.gov/42595189/> ;
  onco:tag "gallbladder-evidence" ;
  schema:sameAs <https://doi.org/10.1016/j.humpath.2026.106234> ;
  schema:datePublished "2026"^^xsd:gYear ;
  schema:author "Angerilli V, Gasparello J, Niero M, et al." ;
  onco:cancers <https://onco.cc/cancers/gallbladder/>, <https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:drugs <https://onco.cc/drugs/zanidatamab/> ;
  onco:terms <https://onco.cc/terms/her2-positive/>, <https://onco.cc/terms/ihc/>, <https://onco.cc/terms/fish/> ;
  onco:trials <https://onco.cc/trials/herizon-btc-01/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-biomarker-validation/> .